Oncolytics Biotech Inc (NAS:ONCY)

$ 0.97 0 (0%) Market Cap: 75.59 Mil Enterprise Value: 62.70 Mil PE Ratio: 0 PB Ratio: 10.78 GF Score: 31/100

Q3 2024 Oncolytics Biotech Inc Earnings Call Transcript
Nov 12, 2024

$1.12 (+3.70%)

Earnings
Q2 2024 Oncolytics Biotech Inc Earnings Call Transcript
Aug 01, 2024

$1.03 (-0.96%)

Earnings
Q4 2023 Oncolytics Biotech Inc Earnings Call Transcript
Mar 07, 2024

$1.04

Earnings
Q3 2023 Oncolytics Biotech Inc Earnings Call Transcript
Nov 03, 2023

$1.72 (-3.91%)

Earnings
Oncolytics Biotech Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 27, 2023
Q2 2023 Oncolytics Biotech Inc Earnings Call Transcript
Aug 14, 2023

$2.05 (+0.99%)

Earnings
Oncolytics Biotech Inc To Discuss Data from the Randomized Phase 2 BRACELET-1 Trial in HR+/HER2 Presentation Transcript
Jun 05, 2023
Oncolytics Biotech Inc Annual Shareholders Meeting Transcript
May 09, 2023
Q1 2023 Oncolytics Biotech Inc Earnings Call Transcript
May 05, 2023

$1.6 (+10.34%)

Earnings
Q4 2022 Oncolytics Biotech Inc Earnings Call Transcript
Mar 03, 2023

$1.59 (-5.36%)

Earnings
Oncolytics Biotech Inc at Society for Immunotherapy of Cancer Conference Transcript
Nov 14, 2022
Q3 2022 Oncolytics Biotech Inc Earnings Call Transcript
Nov 07, 2022

$1.5 (+19.05%)

Earnings
Q2 2022 Oncolytics Biotech Inc Earnings Call Transcript
Aug 11, 2022

$1.3 (+0.04%)

Earnings
Oncolytics Biotech Inc Annual Shareholders Meeting Transcript
Jun 16, 2022
Q1 2022 Oncolytics Biotech Inc Earnings Call Transcript
May 05, 2022

$1.36 (-4.90%)

Earnings
Oncolytics Biotech Inc at Bloom Burton & Co. Healthcare Investor Conference Transcript
May 03, 2022
Oncolytics Biotech Inc at Canaccord Genuity Horizons in Oncology Conference (Virtual) Transcript
Apr 14, 2022
Q4 2021 Oncolytics Biotech Inc Earnings Call Transcript
Mar 03, 2022

$1.62 (-5.81%)

Earnings
Q3 2021 Oncolytics Biotech Inc Earnings Call Transcript
Nov 05, 2021

$2.1 (+3.45%)

Earnings
Q2 2021 Oncolytics Biotech Inc Earnings Call Transcript
Aug 06, 2021

$2.23 (+1.83%)

Earnings
Oncolytics Biotech Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript
Jul 14, 2021
Q1 2021 Oncolytics Biotech Inc Earnings Call and Annual Corporate Update Transcript
May 07, 2021

$2.86 (-2.05%)

Earnings
Oncolytics Biotech Inc Host Key Opinion Leader - Corporate Call Transcript
Apr 12, 2021
Q4 2020 Oncolytics Biotech Inc Earnings Call Transcript
Mar 05, 2021

$2.68 (-12.13%)

Earnings
Q3 2020 Oncolytics Biotech Inc Earnings Call Transcript
Nov 11, 2020

$2.15 (+3.37%)

Earnings
Q2 2020 Oncolytics Biotech Inc Earnings Call Transcript
Aug 04, 2020

$2.15 (+5.39%)

Earnings
Oncolytics Biotech Inc Annual Shareholders Meeting Transcript
May 07, 2020
Q4 2019 Oncolytics Biotech Inc Earnings Call Transcript
Mar 05, 2020

$2.77 (+10.80%)

Earnings
Q3 2019 Oncolytics Biotech Inc Earnings Call Transcript
Nov 12, 2019

$1.02 (+0.99%)

Earnings
Oncolytics Biotech Inc to Discuss Recent Highlights and Expanded Catalysts and Milestones Call Transcript
Sep 05, 2019
Oncolytics Biotech Inc. - Shareholder/Analyst Call Transcript
Jun 05, 2019
Oncolytics Biotech Inc Annual Shareholders Meeting Transcript
May 02, 2019
Oncolytics Biotech Inc. - Special Call Transcript
Apr 11, 2019
Q4 2018 Oncolytics Biotech Inc Earnings Call Transcript
Mar 08, 2019

$1.99 (+6.99%)

Earnings

Q3 2022 Oncolytics Biotech Inc Earnings Call Transcript

Nov 07, 2022 / 01:30PM GMT

Release Date Price: $1.5 (+19.05%)

Transcript

Operator

Good morning, and welcome to Oncolytics Biotech's Third Quarter 2020 Conference Call. (Operator Instructions) Please be advised that this call is being recorded at the company's request.

Now I would like to turn the call over to Jon Patton, Director of Investor Relations and Communications. Please go ahead, sir.

Jon Patton

Oncolytics Biotech Inc. - Director of IR & Communication

Thank you, operator, and good morning, everyone. Earlier this morning, Oncolytics issued 2 press releases. One announcing interim results from the pancreatic cancer cohort of the company's Phase I/II GOBLET trial, and a second providing recent operational highlights and financial results for the third quarter of 2022. The announcements and highlights provided in these press releases will be the topics of today's call. A replay should be available on the Events and Presentations section of the Oncolytics website approximately 2 hours after its completion. After remarks from company management, we'll open the call for Q&A.

As a reminder, various remarks made

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.